AFFIX Labs and leading seat manufacturer Franz Kiel GmbH sign agreement to use Si-Quat

Millions of people rely on public transport infrastructure every day, and this will be critical for economies to reopen following COVID-19 lockdowns worldwide. However, many viruses and bacteria, including the SARS-COV-2 virus, can survive on certain surfaces for up to 3 days, meaning regularly touched areas in public spaces have the potential to be cross-contamination hotspots.

Now, Si-Quat, a durable semi-permanent surface coating developed by AFFIX Labs that has been proven to kill 99.9% of bacteria and viruses including SARS-COV-2, will help make public transport safer as people around the world begin returning to buses and trains. Si-Quat helps prevent cross-contamination by adhering to walls, handles, furniture and other critical contact points with a durable polymerized active ingredient layer that remains in place for up to 12 months and kills 99.9% of viruses and bacteria that come into contact with the treated surface. The coating has been tested and approved as effective against bacteria, viruses and fungi, and has passed the strict EN45545-2 HL3 flammability standard for trains and REG118.3 for buses. Kiel, which has been producing high-quality seating for public transport worldwide for over 75 years, is now presenting Si-Quat to its customers as a new solution for protection in transportation networks. With Si-Quat already registered in several continents, rapid deployment is truly possible. Daniel Fräde, Sales Director of Kiel's Bus Division, said: "We are pleased to be working with AFFIX Labs to bring Si-Quat to public transport systems worldwide. It is easy to apply, it works, and we received great support from the AFFIX Labs team. We hope that our partnership will help countries reopen and restore passenger confidence in public transport once again." "By processing large vehicle fleets across countries worldwide that drive mass movement of people, AFFIX and Kiel Seating can create safe transport interiors that are a vital component of national infrastructure. We are proud to be part of the global effort to create a more future-oriented response to COVID-19 and other transmissible diseases that have the potential to cause pandemics," said Tom Sam, CEO of AFFIX Labs.